These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 30826965)

  • 21. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
    Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
    Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
    Zhu XR; Zheng LZ
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.
    Munari E; Mariotti FR; Quatrini L; Bertoglio P; Tumino N; Vacca P; Eccher A; Ciompi F; Brunelli M; Martignoni G; Bogina G; Moretta L
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
    Xue S; Hu M; Iyer V; Yu J
    J Hematol Oncol; 2017 Apr; 10(1):81. PubMed ID: 28388955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
    Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
    Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Not Available].
    Simonaggio A; Marabelle A
    Bull Cancer; 2018 Dec; 105 Suppl 1():S121-S131. PubMed ID: 30595193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
    Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
    Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
    Otter SJ; Chatterjee J; Stewart AJ; Michael A
    Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):834-843. PubMed ID: 31331818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for esophageal squamous cell carcinoma: a review.
    Mimura K; Yamada L; Ujiie D; Hayase S; Tada T; Hanayama H; Thar Min AK; Shibata M; Momma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2018 Aug; 64(2):46-53. PubMed ID: 30058598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
    Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI
    Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spatiotemporal Changes in Checkpoint Molecule Expression.
    Li W; Qie J; Zhang Y; Chang J
    Adv Exp Med Biol; 2020; 1248():167-200. PubMed ID: 32185711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.